12 reports

  • GROWING APPROVALS IN LUNG CANCER THERAPEUTICS MARKET
  • MARKET PENETRATION OF VARIOUS LUNG CANCER THERAPEUTICS MANUFACTURERS IN GLOBAL (2015)

About Lung Cancer Therapeutics Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes...

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Hoffmann-La Roche Inc.
  • LIST OF PHASE III PIPELINE MOLECULES

About Cancer Monoclonal Antibodies The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Hoffmann-La Roche Inc.
  • MARKET ANALYSIS 2014
  • Vendor landscape

ACCORDING TO THE AMERICAN LUNG ASSOCIATION, LUNG CANCER IS ONE OF THE LEADING CAUSE OF DEATH BY CANCER IN THE US.

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Hoffmann-La Roche Inc.
  • Scope of the report

Roche is one of the major players in the market.

  • Cancer
  • Cervical Cancer
  • Therapy
  • Vaccine
  • Hoffmann-La Roche Inc.
  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition
  • 8.1 REFERENCES

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Hoffmann-La Roche Inc.
  • Idera Pharmaceuticals, Inc.
  • 08.4 HER-2 POSITIVE BREAST CANCER MARKET IN EU
  • 07. Pipeline Analysis

About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated...

  • Breast Cancer
  • Cancer
  • Therapy
  • Celgene Corporation
  • Hoffmann-La Roche Inc.

In the case of node-negative cancers, cancer should be estrogen receptors (ER), progesterone receptor (PR) negative, or associated with one high-risk feature.

  • Cancer
  • United States
  • World
  • Market Size
  • Hoffmann-La Roche Inc.

In the case of node-negative cancers, cancer should be estrogen receptors (ER), progesterone receptor (PR) negative, or associated with one high-risk feature.

  • Cancer
  • United States
  • World
  • Market Size
  • Hoffmann-La Roche Inc.

SGN-LIV##A: This product candidate targets LIV-##, which is active in breast cancer.

  • Cancer
  • Therapy
  • Hoffmann-La Roche Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

HOFFMANN-LA ROCHE ENTERED INTO AN AGREEMENT OF WORTH $## BILLION WITH NEWLINK TO DEVELOP THE CANCER DRUG, NLG##.

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Hoffmann-La Roche Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • 10/18/2017: IMPROVING OUTCOMES FOR PATIENTS WITH A COMMON TYPE OF BLOOD CANCER
  • IMMUNOCORE ENTERS INTO LICENSING AND RESEARCH AGREEMENT WITH GENENTECH FOR CANCER DRUGS

Summary F.Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics that improve the standard of care in major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, neurology and respiratory...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Hoffmann-La Roche Inc.